Serum levels of dehydroepiandrosterone sulfate are associated with a lower risk of mobility-subtype frailty in older Japanese community-dwellers. (February 2023)

• Record Type: Journal Article
• Authors: Zhang, Shu; Otsuka, Rei; Shimokata, Hiroshi; Nishita, Yukiko; Tange, Chikako; Takemura, Marie; Satake, Shosuke
• Is Part Of: Archives of gerontology and geriatrics. Volume 105(2023)
• Publication Date: 2023-02
• Subjects: Dehydroepiandrosterone sulfate -- Physical frailty -- Subtypes; DHEA-S dehydroepiandrosterone sulfate -- NILS-LSA National Institute for Longevity Sciences-Longitudinal Study of Aging -- CLEIA chemiluminescence enzyme immunoassay -- CES-D Center for Epidemiologic Studies of Depression -- MET metabolic equivalent of task -- OR odds ratio -- CI confidence interval -- SD standard deviation -- CFS Clinical Frailty Scale; Aging -- Periodicals; Geriatrics -- Periodicals; Gerontology -- Periodicals; Electronic journals; 305.26
• DOI: 10.1016/j.archger.2022.104846
• Languages: English
• ISSNs: 0167-4943

Abstract

Highlights: Higher serum DHEA-S levels were associated with lower risk of frailty. This was especially true for mobility-subtype frailty. Low serum DHEA-S also showed a trend towards an association with weight loss. Abstract: Purpose: Previous studies suggest that lower serum levels of dehydroepiandrosterone sulfate (DHEA-S) are associated with physical frailty. Associations with subtypes of physical frailty have not been studied. This study aimed to investigate associations between serum DHEA-S levels and physical frailty and its subtypes in older Japanese community-dwellers using panel data. Methods: This study was conducted within the National Institute for Longevity Sciences-Longitudinal Study of Aging (NILS-LSA). Repeated measurement data were collected from 1, 886 older community-dwellers (60–91 years). Frailty was identified according to modified Cardiovascular Health Study criteria (weight loss, weakness, slowness, exhaustion, low physical activity) and was classified into following subtypes: mobility (weakness/slowness), non-mobility (weight loss/exhaustion), and low physical activity. Associations with serum DHEA-S (sex-specific tertiles [T1−T3]) were estimated by random-effects logistic regression models adjusting for age, sex, education, disease history (stroke, hypertension, heart disease, diabetes), smoking status, depressive symptoms, and survey wave. Results: We found an average prevalence of 6.0% for frailty (mobility subtype, 7.0%; non-mobility subtype, 34.8%; low physical activity subtype, 9.4%) across survey waves. Mean (SD) sex-specific DHEA-S levels (μg/dL) at T1, T2, and T3 were 46.8 (20.8), 88.7 (28.4), and 158.0 (58.9), respectively. Compared with T1, the adjusted ORs (95% CIs) for frailty were 0.69 (0.44, 1.08) for T2 and 0.50 (0.30, 0.83) for T3 ( P trend = 0.007). The corresponding values for mobility subtype were 0.80 (0.51, 1.24) for T2 and 0.55 (0.33, 0.90) for T3. Conclusion: Higher serum DHEA-S levels were associated with lower risk of frailty, especially mobility-subtype frailty, in older community-dwellers.